当前位置: X-MOL 学术J. Am. Chem. Soc. › 论文详情
Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer.
Journal of the American Chemical Society ( IF 14.612 ) Pub Date : 2020-01-07 , DOI: 10.1021/jacs.9b10510
Jiaxuan He,Tianhuan Peng,Yongbo Peng,Lili Ai,Zhengyu Deng,Xue-Qiang Wang,Weihong Tan

Triple-negative breast cancer (TNBC) lacks three important receptors, ER, PR, and HER2. It is more aggressive and more likely to relapse after treatment, thus has been identified as one of the most malignant breast cancer types. The development of efficient targeted TNBC therapy is an important research topic in TNBC treatment. We report the development of a new aptamer-drug conjugate (ApDC), AS1411-triptolide conjugate (ATC), as targeted therapy for the treatment of TNBC with high efficacy. The conjugate possesses excellent specificity and high cytotoxicity against the MDA-MB-231 cell line. The advantages of our newly invented ATC are further highlighted by its excellent in vivo anti-TNBC efficacy and negligible side effects toward healthy organs.
更新日期:2020-01-14

 

全部期刊列表>>
物理学研究前沿热点精选期刊推荐
chemistry
《自然》编辑与您分享如何成为优质审稿人-信息流
欢迎报名注册2020量子在线大会
化学领域亟待解决的问题
材料学研究精选新
GIANT
自然职场线上招聘会
ACS ES&T Engineering
ACS ES&T Water
ACS Publications填问卷
屿渡论文,编辑服务
阿拉丁试剂right
南昌大学
王辉
南方科技大学
刘天飞
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
天合科研
x-mol收录
X-MOL
苏州大学
廖矿标
深圳湾
试剂库存
down
wechat
bug